---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-22-000012"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:41:12.584740+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports 2021 net loss $50M, cash $157.5M; IND filings on track

## Summary
- Net loss $17.9M in Q4 2021 ($7.4M Q4 2020); full-year loss $50.0M ($15.0M 2020).
- Cash $157.5M at Dec 31, 2021 ($92.6M Dec 31, 2020); runway through at least Q2 2023.
- R&D expenses $35.3M in 2021 ($16.6M 2020); G&A $14.8M ($5.8M).
- IND for WTX-124 expected Q2 2022; IND for WTX-330 early Q3 2022.
- Announced clinical trial collaboration with Merck for WTX-124 + Keytruda in solid tumors.

## SEC filing metadata
- accession: 0001785530-22-000012
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000012/0001785530-22-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000012/howl-20220324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-22-000012
- JSON: https://secwatch.observer/filing/0001785530-22-000012.json
- Plain text: https://secwatch.observer/filing/0001785530-22-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.